29 July 2010
[17-10]

APPLICATION A1036
LIPASE AS A PROCESSING AID (ENZYME)
APPROVAL REPORT

Executive Summary

Purpose

Food Standards Australia New Zealand (FSANZ) received an Application from DSM Food Specialties on 5 October 2009 seeking approval to permit a protein engineered lipase produced from genetically modified Aspergillus niger expressing a gene based on the lipase encoding gene sequences of various Fusarium species. The engineered lipase gene derived from Fusarium culmorum contains the lipase gene sequences of several Fusarium species, as well as several changes unique to the current lipase.

Lipase (EC 3.1.1.3) hydrolyses ester bonds of triacylglycerol to release free fatty acids from the glycerol backbone. It belongs to the subclass of carboxylic ester hydrolases. The proposed use of this lipase is in bakery applications where its technological function is to enhance the gas holding capacity of the dough. This leads to increased stability of the dough upon proofing, increasing loaf volume and improving loaf shape and oven spring post baking. Further claimed effects are improved crumb structure and softness.

A pre-market assessment of the safety of the enzyme, including the source and donor organisms, as well as assessment of the technological suitability, is required prior to any approval being granted. Processing aids used in food manufacture are regulated under Standard 1.3.3 which currently lists approvals for lipase from a number of other sources.

Use of this lipase has already been approved in both Denmark and Russia, whilst the French Food Safety Authority (Agence Française de Sécurité Sanitaire des Aliments; AFSSA) has endorsed the safety of the enzyme preparation with marketing authorization expected during 2010. Further, in response to a submission for assessment of self-GRAS determination (GRN: 296) in the United States, a ‘no-questions’ letter was received.


The Application was assessed under the General Procedure.
Risk Assessment

The risk assessment has considered the technological suitability, the safety and identity of the donor and host microorganisms, and safety of the lipase enzyme preparation.

Key findings of the evaluation are:

- Based on the available evidence, lipase produced in *A. niger* is considered safe for use in foods for human consumption.
- The use of *A. niger* as the host organism is a well-characterised expression system for the production of enzymes and has a long history of safe use.
- Enzymes from *Fusarium* species are generally considered to be safe and several other *Fusarium* lipases have been approved for use by FSANZ.
- The evidence shows that this recombinant lipase is likely to be proteolytically degraded in the human gastrointestinal tract.
- There is no evidence of toxicity at any of the high doses tested in a 90-day repeat dose study. The No Observed Adverse Effect Level (NOAEL) was 2135 mg/kg bw/day, the highest dose tested. There was also no evidence of genotoxicity.
- Based on the reviewed toxicological data, it was concluded that in the absence of any identifiable hazard, an Acceptable Daily Intake (ADI) does not need to be specified.
- The ADI for enzyme preparations produced by *A. niger* is ‘not specified’ by JECFA.
- There is no evidence of any mycotoxins associated with the enzyme preparation.
- The stated purpose for this lipase is to improve the gas holding capacity of dough for bread making. When used in the form and amounts prescribed, the lipase is technologically justified and achieves its stated purpose.

Assessing the Application

In assessing the Application and the subsequent development of a food regulatory measure, FSANZ has had regard to the following matters as prescribed in section 29 of the *Food Standards Australia New Zealand Act 1991* (FSANZ Act):

- whether costs that would arise from a food regulatory measure developed or varied as a result of the Application outweigh the direct and indirect benefits to the community, Government or industry that would arise from the development or variation of the food regulatory measure
- whether other measures (available to the Authority or not) would be more cost-effective than a variation to Standard 1.3.3
- any relevant New Zealand standards
- any other relevant matters.
Decision

To approve the draft variation to Standard 1.3.3 to permit the use of a protein engineered variant of lipase produced by a genetically modified Aspergillus niger as a processing aid.

Reasons for Decision

An amendment to the Code approving the use of the lipase enzyme preparation as a processing aid in Australia and New Zealand is approved on the basis of the available evidence for the following reasons:

- A detailed safety assessment has concluded that the use of the enzyme does not raise any public health and safety concerns.
- The source organism, A. niger, has an established safe history of use in the production of food enzymes.
- Use of the lipase as a processing aid is technologically justified and would be expected to provide benefits to food manufacturers and consumers.
- Permitting use of the enzyme would not impose significant costs for government agencies, consumers or manufacturers.
- The proposed draft variation to the Code is consistent with the section 18 objectives of the FSANZ Act.
- There are no relevant New Zealand standards.

Labelling

Standard 1.5.2 – Food produced using Gene Technology, outlines provisions for labelling of foods produced using gene technology. Although processing aids are not normally subject to labelling on the final food, under clause 4(1)(d) of Standard 1.5.2, labelling requirements do apply where novel DNA and/or novel protein from the processing aid remains present in the final food.

Food produced using this lipase is required to be labelled ‘genetically modified’ in conjunction with the name of the processing aid where novel protein remains in the final food.

Lipase produced by a genetically modified strain of A. niger is not considered to be allergenic. Wheat flour is used to formulate the commercial enzyme preparation, hence the product triggers labelling provisions set forth in Standard 1.2.3 – Mandatory Warning and Advisory Statements and Declarations, for the declaration of cereals containing gluten.

Consultation

Public submissions were invited on the Assessment Report between 7 April 2010 and 19 May 2010. Comments were specifically requested on the scientific aspects of this Application, including the technological function and any information relevant to the safety assessment of the enzyme. A total of 16 submissions were received as a result of the public consultation. A summary of these is included at Attachment 2 to this Report.
As this Application was assessed as a General Procedure, there was one round of public comment following the preparation of an Assessment Report. Responses to the Assessment Report were used to develop this Approval Report, with the main issues raised in submissions specifically discussed.
CONTENTS

INTRODUCTION ......................................................................................................................................................... 2

1. THE ISSUE / PROBLEM ........................................................................................................................................... 2

2. CURRENT STANDARD .................................................................................................................................................. 2
  2.1 Current Standard ................................................................................................................................................... 2
  2.2 International regulations ....................................................................................................................................... 3
  2.3 Nature of the Enzyme and Source of Organism ................................................................................................. 3
  2.4 Technological purpose ........................................................................................................................................... 3

3. OBJECTIVES .............................................................................................................................................................. 3

4. QUESTIONS TO BE ANSWERED .................................................................................................................................. 4

RISK ASSESSMENT ............................................................................................................................................................ 4

5. RISK ASSESSMENT SUMMARY .................................................................................................................................. 5
  5.1 Safety Assessment .................................................................................................................................................. 5
  5.2 Dietary Exposure Assessment ............................................................................................................................... 5
  5.3 Technological Justification .................................................................................................................................... 6
  5.4 Production of the enzyme ...................................................................................................................................... 6
  5.5 Allergenicity .......................................................................................................................................................... 7

RISK MANAGEMENT ........................................................................................................................................................ 7

6. ISSUES RAISED ............................................................................................................................................................. 7
  6.1 Risk Management Strategy ..................................................................................................................................... 7

7. OPTIONS ........................................................................................................................................................................ 8

8. IMPACT ANALYSIS .................................................................................................................................................... 8
  8.1 Affected Parties ...................................................................................................................................................... 8
  8.2 Benefit Cost Analysis .............................................................................................................................................. 8
  8.3 Comparison of Options ......................................................................................................................................... 9

COMMUNICATION AND CONSULTATION STRATEGY ............................................................................................... 9

9. Communication .......................................................................................................................................................... 9

10. CONSULTATION .......................................................................................................................................................... 10
  10.1 Public Consultation .............................................................................................................................................. 10
  10.2 Issues raised in submissions ............................................................................................................................... 10
  10.3 World Trade Organization (WTO) ..................................................................................................................... 12

CONCLUSION .................................................................................................................................................................... 13

11. CONCLUSION AND DECISION ................................................................................................................................ 13
  11.1 Reasons for Decision ........................................................................................................................................... 13

12. IMPLEMENTATION AND REVIEW ................................................................................................................................ 14

ATTACHMENTS ............................................................................................................................................................... 14

  ATTACHMENT 1- DRAFT VARIATION TO THE AUSTRALIA NEW ZEALAND FOOD STANDARDS CODE .............................................................................................................................. 15
  ATTACHMENT 2- SUMMARY OF PUBLIC SUBMISSIONS ON THE ASSESSMENT REPORT ............ 16

SUPPORTING DOCUMENT
The following material, which was used in the preparation of this Approval Report, is available on the FSANZ website at: http://www.foodstandards.gov.au/foodstandards/applications/applicationa1036lipa4582.cfm

SD1: Risk Assessment Report
Introduction

Food Standards Australia New Zealand (FSANZ) received an Application from DSM Food Specialties on 5 October 2009 seeking approval to permit a protein engineered lipase produced from *A. niger* expressing a gene based on the lipase encoding gene sequences of various *Fusarium* species. The protein engineered lipase shows approximately 82% homology to the wild-type lipase of *F. culmorum*, as well as containing lipase gene sequences of several *Fusarium* species, and several unique changes. The marketing name for this enzyme preparation is Panamore Golden.

Lipase (EC 3.1.1.3) hydrolyses ester bonds of triacylglycerol to release free fatty acids from the glycerol backbone. It belongs to the subclass of carboxylic ester hydrolases. The proposed use of this lipase is in bakery applications where its technological function is to enhance the gas holding capacity of the dough. This leads to increased stability of the dough upon proofing, increasing loaf volume and improving loaf shape and oven spring post baking. Further claimed effects are improved crumb structure and softness.

1. The Issue / Problem

The Applicant proposes the use of a protein engineered lipase produced from a genetically modified strain of *A. niger* as a processing aid to enhance the gas holding capacity of bread dough, leading to increased dough stability upon proofing.

A pre-market assessment and approval is required before any new processing aid is permitted. Consideration of a safety assessment of the enzyme, including the source and donor organisms, as well as assessing the technological function of the enzyme for its claimed use is required before any permission may be granted.

2. Current Standard

2.1 Current Standard

Processing aids used in food manufacture are regulated under Standard 1.3.3.

A processing aid is described in clause 1 of Standard 1.3.3 as:

A substance listed in clauses 3 to 18, where –

(a) the substance is used in the processing of raw materials, foods or ingredients, to fulfil a technological purpose relating to treatment or processing, but does not perform a technological function in the final food; and

(b) the substance is used in the course of manufacture of a food at the lowest level necessary to achieve a function in the processing of that food, irrespective of any maximum permitted level specified.

Table to clause 17- Permitted enzymes of microbial origin, contains a list of permitted enzymes and the microorganism/s (including genetically modified organisms) from which they can be produced.

Lipase, triacylglycerol (EC 3.1.1.3) is already a permitted processing aid from a number of other microbial and animal sources as listed in Standard 1.3.3.
2.2 **International regulations**

Use of this lipase has already been approved in both Denmark and Russia, whilst the French Food Safety Authority (Agence Française de Sécurité Sanitaire des Aliments; AFSSA) has endorsed the safety of the enzyme preparation with marketing authorisation expected during 2010. Further, in response to a submission for assessment of self-GRAS determination (GRN: 296) in the United States, a ‘no-questions’ letter was received.


2.3 **Nature of the Enzyme and Source of Organism**

Lipase, triacylglycerol (EC 3.1.1.3) is a hydrolase enzyme belonging to the subclass of carboxylic ester hydrolases. Lipase hydrolyses ester bonds of triacylglycerol to release free fatty acids from the glycerol backbone.

The lipase described in this Application hydrolyses the following reaction:

\[
\text{Triacylglycerol} + \text{H}_2\text{O} \rightarrow \text{diacylglycerol} + \text{a carboxylate}
\]

The source organism used to produce this lipase is a genetically modified (GM) strain of *A. niger* with a history of safe use in the production of food enzymes. The modified *A. niger* expresses a gene based on the lipase encoding gene sequences of various *Fusarium* species. The protein engineered lipase shows approximately 82% homology to the wild-type lipase of *F. culmorum*, as well as containing lipase gene sequences of several *Fusarium* species, and several unique changes.

2.4 **Technological purpose**

The enzyme preparation is proposed to be used in bread products to enhance the gas holding capacity of the dough resulting in increased stability of the dough upon proofing. This then correlates to an increased loaf volume, improved loaf shape and oven spring post baking. Further effects are improved crumb structure and softness. Reduced reliance on flour/bread improvers to deal with seasonal variations of flour is also a claimed benefit.

3. **Objectives**

The objective of this assessment is to determine whether it is appropriate to amend Standard 1.3.3 to permit the use of the engineered lipase enzyme from a genetically modified *A. niger* strain for use as a processing aid.

In developing or varying a food standard, FSANZ is required by its legislation to meet three primary objectives which are set out in section 18 of the FSANZ Act. These are (in descending priority order):

- the protection of public health and safety; and
- the provision of adequate information relating to food to enable consumers to make informed choices; and
- the prevention of misleading or deceptive conduct.
In developing and varying standards, FSANZ must also have regard to:

- the need for standards to be based on risk analysis using the best available scientific evidence;
- the promotion of consistency between domestic and international food standards;
- the desirability of an efficient and internationally competitive food industry;
- the promotion of fair trading in food; and
- any written policy guidelines formulated by the Ministerial Council.

The Ministerial Council Policy Guideline: *Addition to Food of Substances other than Vitamins and Minerals* includes policy principles in regard to substances added to achieve a solely technological function such as food additives and processing aids. According to these guidelines, permissions should be granted where:

- the purpose for adding the substance can be articulated clearly by the manufacturer as achieving a solely technological function (i.e. the ‘stated purpose’)
- the addition of the substance to food is safe for human consumption
- the amounts added are consistent with achieving the technological function
- the substance is added in a quantity and a form which is consistent with delivering the stated purpose
- no nutrition, health or related claims are to be made in regard to the substance.

4. **Questions to be answered**

For this Application, FSANZ has considered the following risk assessment questions:

- Is the enzyme safe for the proposed use?
  - Are the donor and source organisms safe for producing this lipase?
  - Are there any potential allergenicity concerns with any components associated with the production process?
  - Does the lipase share homology with known allergens?
- Does the enzyme achieve its stated technological purpose?
  - Is the quantity and form proposed for addition, consistent with proposed use?

**RISK ASSESSMENT**

A detailed assessment of the safety and functionality of the lipase has been undertaken for this Application. The summary and conclusions from this risk assessment (Supporting Document 1) are presented below.

In addition to information supplied by the Applicant, other available resource materials including published scientific literature and general technical information were used in this assessment.
5. **Risk Assessment Summary**

The risk assessment has considered the technological suitability, the safety and identity of the donor and host microorganisms, and safety of the enzyme preparation of lipase.

Based on the available data, it was concluded no toxicological or hazard-related concerns with the enzyme or the donor or host microorganisms were revealed which would preclude permitting use of the enzyme as a food processing aid. The absence of any specific hazards being identified is consistent with lipase undergoing normal proteolytic digestion in the gastrointestinal tract.

It was further concluded that the Application clearly articulates the stated purpose for this lipase, namely to improve the gas holding capacity of the dough and the evidence submitted in support of the Application provides adequate assurance that the lipase, in the form and amounts added, is technologically justified and has been demonstrated to be effective in achieving its stated purpose.

The available data are considered sufficient to support the conclusions of this risk assessment in regard to the safety and suitability of this lipase for its stated purpose.

5.1 **Safety Assessment**

The safety assessment of lipase from a GM *A. niger*, concluded:

- There is no evidence of any toxicity in a 13-week oral toxicity study in rats.
- The NOAEL was 2135 mg/kg bw (1008 mg Total Organic Solids (TOS) or 20389 DSM Lipase Units (DLU)) in males and 2250 mg/kg bw/day (1062 mg TOS or 21487 DLU) in females.
- There is no evidence of genotoxicity;
- There is no evidence of any mycotoxin production associated with the enzyme preparation.

Based on the available data, it was concluded no toxicological or hazard-related concerns with the enzyme or the donor or host microorganisms were revealed which would preclude permitting use of the enzyme as a food processing aid. The absence of any specific hazards being identified is consistent with lipase undergoing normal proteolytic digestion in the gastrointestinal tract.

In 1990 the JECFA reviewed its initial numerical Acceptable Daily Limit (ADI) decision to set an ADI of *A. niger* enzyme preparations as 'not specified' (JECFA, 1990).

5.2 **Dietary Exposure Assessment**

Processing aids perform their technological function during the manufacture of food and are therefore either not present in the final food or present only at very low levels. The Applicant has provided estimated daily intake (EDI) data for the lipase based on residual enzyme level data from their inactivation trials and 90th percentile food intake data from The Netherlands and USA (Section G4 in the Application). The EDI was determined to be between 0.041-0.675 DLU/kg bw based on The Netherlands data and 0.039-0.65 DLU/kg bw using the US data.
This lipase is expected to be inactivated during baking and have no further technical effect after baking. Any residual enzyme would be present as denatured protein and would undergo normal proteolytic digestion in the gastrointestinal tract.

FSANZ has reviewed and accepts the submitted dietary exposure evidence and this together with the allocated ADI supports the determination that further dietary exposure assessment is unnecessary.

5.3 Technological Justification

Apart from the reaction described in Section 2.3, the lipase can also act on ester bonds of other lipid substrates, including (polar) diacyl lipids, phospholipids and glycolipids, such as galactolipids. Depending on the lipids present in the application, one of the above activities will be more prevalent than the other.

The lipase’s technological effect in bakery applications is to enhance the gas holding capacity of the dough leading to increased stability of the dough upon proofing. This results in an increased loaf volume, improved loaf shape and oven spring post baking. Further effects are improved crumb structure and softness. Reduction in manufacturer’s reliance on flour/bread improvers to deal with seasonal variations of flour is also a proposed benefit of the enzyme’s use.

The mechanisms underlying these technological effects are mainly based on the generation of polar lipids from the lipids naturally present in the dough. The natural content of lipids in wheat flour is approximately 2.5% (w/w), comprising both polar and apolar lipids. The gas holding capacity of dough is highly influenced by the lipid composition of the flour. The higher the content of highly polar monoacyl lipids, the better the gas-holding capacity and thus the baking performance will be.

The baking trial and inactivation evidence presented provides adequate assurance that the enzyme is technologically justified and has been demonstrated to be effective in achieving its stated purpose. Adequate assurance is also provided that the enzyme in the form and amounts prescribed are consistent with achieving its technological function.

5.4 Production of the enzyme

The lipase is produced by a submerged fermentation process using appropriate substrates and nutrients followed by several filtration and purification steps. The fermentation process consists of two steps: inoculum fermentation and main fermentation. Biosynthesis and excretion of the lipase by the production organism occurs during the main fermentation phase. Once fermentation is stopped, the production organism is killed off using a validated procedure. The cell material is separated from the lipase by means of a simple filtration process (broth filtration, followed by polish filtration and a germ reduction filtration). The lipase content in the fermentation broth is then concentrated by ultrafiltration. The ultrafiltered (UF) concentrate is then spray dried in the presence of wheat flour and subsequently blended with granulated wheat flour to the desired lipase activity.

The fermentation process is carried out using Good Manufacturing Practice.

Specifications for identity and purity written for the enzyme preparation comply with the international specifications relevant for enzymes prepared by (JECFA, 2006). These specifications are primary reference sources listed in clause 2 of Standard 1.3.4 – Identity and Purity.
The expression organism for the lipase is a genetically modified *A. niger* strain. *A. niger* has a history over several decades of safe use as a production organism for food enzymes. A number of enzymes produced in *A. niger* have been evaluated for safety by the JECFA and are considered to be non-toxic. The acceptable daily intake (ADI) for these enzymes has been determined to be 'not specified' on account of its low toxicity. It is also a permitted source of a number of enzymes in the Code.

The modified lipase is encoded by a novel gene sequence derived from a number of lipase genes from the fungal genus *Fusarium*. The primary homology is to the lipase gene of *F. culmorum* (approximately 82% amino acid identity). Enzymes from *Fusarium* species are generally considered to be safe, and several other *Fusarium* lipases have been approved for use by FSANZ.

### 5.5 Allergenicity

The Applicant presented the results of a bioinformatic assessment of the lipase protein. These data were also presented to the USFDA for their GRAS assessment. In the analysis, the lipase sequence was compared with the Allermatch database to identify sequences of 35% or greater homology with known allergens. No significant matches were found between this lipase and known allergens.

Wheat flour is used to formulate the commercial enzyme preparation, hence the product triggers labelling provisions set forth in Standard 1.2.3 – Mandatory Warning and Advisory Statements and Declarations, for the declaration of cereals containing gluten.

### Risk Management

#### 6. Issues raised

**6.1 Risk Management Strategy**

The risk assessment concludes that use of a protein engineered lipase sourced from genetically modified *A. niger* as a processing aid does not pose a public health and safety risk and that its proposed use is technologically justified.

The engineered lipase gene derived from *F. culmorum* contains the lipase gene sequences of several *Fusarium* species, as well as several changes unique to the current lipase. The lipase gene from *F. culmorum* has been optimised for performance in bakery applications using specific mutations.

Labelling addresses the objective set out in section 18(1)(b) of the FSANZ Act; the provision of adequate information relating to food to enable consumers to make informed choices.

The commercial enzyme product triggers labelling provisions set forth in Standard 1.2.3 for the declaration of cereals containing gluten, as wheat flour is used to standardise the product.

Standard 1.5.2 outlines provisions for labelling of foods produced using gene technology. Although processing aids are not normally subject to labelling on the final food, under clause 4(1)(d) of Standard 1.5.2, labelling requirements do apply for processing aids where novel DNA and/or novel protein from the processing aid remains present in the final food. Novel DNA and/or novel protein is defined in clause 4(1) of Standard 1.5.2 as being; DNA or a protein which, as a result of the use of gene technology, is different in chemical sequence or structure from DNA or protein present in counterpart food which has not been produced using gene technology.
If approved, food produced using this lipase would be required to be labelled ‘genetically modified’ in conjunction with the name of the processing aid where novel protein remains in the final food.

Processing aid approvals are not regulated under Standard 1.5.2. Therefore no variation or amendment to the Table to clause 2 is necessary.

7. Options

As processing aids require a pre-market approval under Standard 1.3.3, it is not appropriate to consider non-regulatory options. Consequently, two regulatory options have been identified for this Application:

Option 1: Reject the Application

Option 2: Prepare a draft variation to amend Standard 1.3.3 to permit the use of lipase produced by a genetically modified A. niger as a processing aid.

8. Impact Analysis

FSANZ is required to consider the impact of various regulatory and non-regulatory options on all sectors of the community, especially relevant stakeholders who may be affected by this Application. The benefits and costs associated with the proposed amendment to the Code have been analysed using regulatory impact principles.

In accordance with the Best Practice Regulation Guidelines, completion of a preliminary assessment for this application indicated a low or negligible impact. The Office of Best Practice Regulation has advised that the application appears to be of a minor or machinery nature; notified approval of the preliminary assessment (RIS ID: 11031) and further advised that a Regulatory Impact Statement (RIS) is not required.

8.1 Affected Parties

The affected parties may include:

- those sectors of the food industry wishing to use this lipase as a processing aid
- consumers of food products in which lipase is used as a processing aid
- Government agencies with responsibility for compliance and enforcement of the Code.

8.2 Benefit Cost Analysis

8.2.1 Option 1: Reject the Application

This option is the status quo, with no changes required to the Code.

- Food industries and consumers may be disadvantaged as they would be unable to capture the benefits conferred by the technological function of the new enzyme.
- There is no identified impact on government agencies.
8.2.2 Option 2: Approve the Application

- Allows food industry choice.
- Manufacturers may benefit as improvements to product quality may improve market share.
- There may be benefits for manufacturers through use of different processing techniques and potential cost savings associated with reduced reliance on bread/dough improvers to deal with seasonal variations in raw ingredients.
- Consumers may benefit from foods produced using lipase through accessibility to products of consistent high quality.
- There should be no additional costs imposed on consumers.
- There is not predicted to be any significant cost impost on jurisdictions to determine compliance with the proposed amendment compared with current monitoring and compliance activities.

8.3 Comparison of Options

Option 1 appears to provide no apparent benefits to industry, consumers or government. It denies industry access to a safe, technologically justified processing aid for use in bread.

Option 2 does not appear to impose any significant costs on industry, consumers or government. It provides benefits to industry in terms of product innovation and possible reductions in processing costs. Potential benefits may also exist for both industry and consumers in the provision of products with consistent high quality.

In considering the costs and benefits associated with both options, Option 2 would be the preferred option as it conveys benefits for the food industry and consumers without imposing significant costs for government agencies, consumers or manufacturers.

Communication and Consultation Strategy

9. Communication

FSANZ has applied a basic communication strategy to this Application. The strategy involved advertising the availability of the assessment reports for public comment in the national press and placing the reports on the FSANZ website.

The process by which FSANZ considers standard matters is open, accountable, consultative and transparent. The purpose of inviting public submissions is to obtain the views of interested parties on the issues raised by the application and the impacts of regulatory options. The issues raised in the public submissions are evaluated and addressed in FSANZ assessment reports.

The Applicant, individuals and organisations making submissions on this Application will be notified at each stage of the Application. The decision of the FSANZ Board to approve the variation to the Code will be notified to the Ministerial Council. If a request to review the decision is not made by the Ministerial Council, the variation will be gazetted. Stakeholders (including the Applicant) and submitters will be advised of the notification and gazettal in the national press and on the FSANZ website.
10. Consultation

10.1 Public Consultation

The Assessment Report was notified for public comment between 7 April 2010 and 19 May 2010. Comments were specifically requested on the scientific aspects of the Application including the technological function and any safety considerations, as well as information relating to any potential costs or benefits associated with use of this lipase as a processing aid. As this Application was assessed under a General Procedure, only one round of public comment was applicable.

Sixteen submissions were received during the public consultation period. A summary of these is provided in Attachment 2. One late submission was also received.

Two government agencies and one professional organisation all supported the application. They agreed that the enzyme was technologically justified, demonstrated to be effective for the stated purpose and that no public health and safety concerns had been identified.

Opposition to the Application was recorded from 13 submitters: 12 private consumers and one consumer advocacy group. An anti-GM campaign letter was used by six submitters with the remainder also stating opposition to foods produced using gene technology.

A number of general GM food issues were raised by submitters, such as the safety of GM food, GM food labelling, long-term feeding studies and the nature and source of data used to inform the safety assessment. Responses to these are available on the FSANZ website.

FSANZ has taken submitters’ comments into account in preparing the Approval Report for this Application. Discussed below are specific concerns raised in submissions for further consideration.

10.2 Issues raised in submissions

10.2.1 Unreasonable costs to consumers seeking to avoid GM ingredients

Six private submitters suggested consumers wishing to avoid genetically modified foods would be disadvantaged by the approval of this lipase.

10.2.1.1 Response

Despite this being a common theme among some submitters, there was no elaboration of the nature of these costs. Foods containing GM protein are required to be labelled in accordance with provisions set out in Standard 1.5.2. Thus consumers can, if they wish, avoid GM foods. Therefore, FSANZ considers the current labelling requirements appropriate.

10.2.2 Enzyme identity

Gene Ethics claims FSANZ is confused and wrong in referring to this protein as lipase, when it differs substantially from the *F. culmorum* sequence.

10.2.2.1 Response

There are many thousands of lipases in nature. A lipase is simply the name for a protein that

---

catalyses the hydrolysis of ester bonds in lipids. Thus any protein that performs this function is, in fact, a lipase. The Code lists proteins from 14 different organisms which are lipases. The enzyme in question catalyses the hydrolysis of ester bonds in lipids and is therefore a lipase.

10.2.3 No history of safe use

Gene Ethics repeatedly states throughout their submission that the lipase differs by more than a third from the wild-type *F. culmorum* lipase and therefore that this protein has no history of safe use.

10.2.3.1 Response

The Risk Assessment states the lipase gene is 82% identical to the lipase gene of *F. culmorum*. This constitutes a difference of 18% (100-82=18), not ‘more than a third’ as stated by the submitter.

The section referring to the ‘donor strain’ is just one section of the safety assessment. The intention of this section is to identify whether the strain *per se* has a history of safe use, not the enzyme itself. That is, does the strain produce toxins? Is the strain associated with infections in healthy people? Does the strain cause food poisoning? Regardless of the sequence identity of the enzyme in question, the original organism (*Fusarium culmorum*) has a history of safe use.

Lipases bearing almost no sequence identity to one another are regularly consumed with no ill-effects.

10.2.4 Substantial equivalence

The submission from Gene Ethics states that FSANZ uses the principle of substantial equivalence in their safety assessments. They further state the lipase is substantially different from the comparator (*F. culmorum* lipase) and therefore cannot be called ‘substantially equivalent’.

10.2.4.1 Response

This enzyme is a processing aid. Each processing aid is treated as an entity and is assessed as such. At no time is the concept of ‘substantial equivalence’ used. The wild-type lipase is, therefore, not a comparator.

10.2.5 The bioinformatic assessment is insufficient

Gene Ethics claims that the bioinformatic assessment is insufficient evidence of the lack of allergenicity. They state that multiple databases should be required.

10.2.5.1 Response

The bioinformatic assessment supplied by the Applicant used the Allermatch database. This database consists of three different databases, including Swiss Prot. These databases contain every known allergen and isoallergen, and so searching several databases, each of which contains only a subset of the Allermatch database, is unnecessary.
10.2.6  Interaction with gluten in the human digestive tract

Gene Ethics notes that the product will be formulated with wheat flour, that the lipase family is among the same family as human digestive enzymes, and that more evidence should be required from the Applicant to show how the product interacts with gluten in the human digestive tract.

10.2.6.1 Response

Lipases catalyse the hydrolysis of lipids. Glutens (gliadin and glutenin) are not lipids, but rather proteins. Therefore, there will be no interaction between lipase and these proteins.

10.2.7  Technological function

Gene Ethics claims that a benefit of 'softer crumbs' is insufficient technological justification. They further state this lipase is unnecessary when other non-GM lipases are available.

10.2.7.1 Response

In assessing whether to grant permissions for use of new processing aids, FSANZ is required to conduct a pre-market safety assessment. FSANZ also has to have regard to the Ministerial Policy Guideline on The Addition to Food of Substances other than Vitamins and Minerals for substances added to achieve a purely technological function, such as processing aids. The Guideline states that these should be permitted where the substance is safe for human consumption, the purpose of addition is achieving a solely technological function and that the amounts and form prescribed are consistent with achieving the stated purpose. FSANZ’s consideration does not extend to an evaluation of the relevant merits of the processing aid under assessment, compared to those already available.

The Risk Assessment concluded that this lipase is effective and that its use is technologically justified in the form and amounts prescribed for the stated purpose. Further, the safety assessment concluded that there are no public health and safety issues associated with its prescribed use.

10.2.8  Assessment under Standard 1.5.2

Gene Ethics states this enzyme is being assessed under Standard 1.5.2 and that if it were indeed 'lipase' rather than a novel GM enzyme, there would be no need to assess under Standard 1.5.2.

10.2.8.1 Response

The lipase in question is a processing aid and these are regulated under Standard 1.3.3 not Standard 1.5.2. Labelling provisions of Standard 1.5.2 apply where novel DNA and/or novel protein from the processing aid remains present in the final food. As described in Section 1 of this report, all new processing aids are subject to a pre-approval safety assessment.

10.3  World Trade Organization (WTO)

As members of the World Trade Organization (WTO), Australia and New Zealand are obligated to notify WTO member nations where proposed mandatory regulatory measures are inconsistent with any existing or imminent international standards and the proposed measure may have a significant effect on trade.
Amending the Code to allow lipase as a permitted processing aid (enzyme) is unlikely to have a significant effect on international trade as the enzyme preparation complies with international standards for food enzymes as gazetted by JECFA and the Food Chemicals Codex.

Notification to WTO under FSANZ’s obligations under the WTO Technical Barriers to Trade or Sanitary and Phytosanitary Measures Agreements was not considered necessary.

**Conclusion**

11. **Conclusion and Decision**

This Application has been assessed against the requirements of section 29 of the FSANZ Act with FSANZ recommending the proposed draft variation to Standard 1.3.3.

The Assessment Report concluded that use of a protein engineered lipase produced by a genetically modified *A. niger* as a processing aid, is technologically justified and does not pose a public health and safety risk.

An amendment to the Code giving permission for the use of this lipase as a processing aid in Australia and New Zealand is recommended on the basis of the available scientific information.

The proposed variation is provided in **Attachment 1**.

<table>
<thead>
<tr>
<th>Decision</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>To approve the draft variation to Standard 1.3.3 to permit the use of a protein engineered variant of lipase produced by a genetically modified <em>Aspergillus niger</em> as a processing aid.</strong></td>
</tr>
</tbody>
</table>

11.1 **Reasons for Decision**

An amendment to the Code approving the use of this lipase as a processing aid in Australia and New Zealand is proposed on the basis of the available evidence for the following reasons:

- A detailed safety assessment has concluded that the use of the enzyme does not raise any public health and safety concerns.

- The source organism, *A. niger* is regarded as non-toxigenic and has a safe history of use in production of food enzymes.

- Use of lipase produced from a GM *A. niger* as a processing aid is technologically justified and would be expected to provide benefits to food manufacturers and consumers.

- Permitting use of the enzyme would not impose significant costs for government agencies, consumers or manufacturers.

- The proposed draft variation to the Code is consistent with the section 18 objectives of the FSANZ Act.
• There are no relevant New Zealand standards.

12. Implementation and Review

The FSANZ Board’s decision will be notified to the Ministerial Council. Following notification, the proposed draft variation to the Code is expected to come into effect on gazettal, subject to any request from the Ministerial Council for a review of FSANZ’s decision.

ATTACHMENTS

1. Draft variation to the *Australia New Zealand Food Standards Code*
2. Summary of Public Submissions on the Assessment Report
Draft variation to the *Australia New Zealand Food Standards Code*

Subsection 94 of the FSANZ Act provides that standards or variations to standards are legislative instruments, but are not subject to disallowance or sunsetting

To commence: on gazettal

[1] Standard 1.3.3 of the Australia New Zealand Food Standards Code is varied by inserting in the Table to clause 17 –

<table>
<thead>
<tr>
<th>Lipase, triacylglycerol, protein engineered variant</th>
<th>Aspergillus niger, containing the gene for lipase, triacylglycerol isolated from <em>Fusarium culmorum</em></th>
</tr>
</thead>
</table>
Summary of Public Submissions on the Assessment Report

Sixteen submissions were received during the public consultation period in response to the Assessment Report. One late submission was also received.

Support for the Application was noted from two government agencies and one professional organisation. They agreed that the enzyme was technologically justified, demonstrated to be effective for the stated purpose and that no public health and safety concerns had been identified.

Opposition was recorded from 13 submitters: 12 private consumers and one consumer advocacy group. An anti-GM campaign letter was used by six submitters with the remainder also stating opposition to foods produced using gene technology.

A summary of all submissions received is provided in the below table.

<table>
<thead>
<tr>
<th>Submitter</th>
<th>Group</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hsieh Lim</td>
<td>Private</td>
<td>• Opposes</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Does not want these on market until extended research (&gt;30 years) proves safety</td>
</tr>
<tr>
<td>Anna Clements</td>
<td>Private</td>
<td>• Opposes</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Cites concern over safety of GM products</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Claims GM labelling is inadequate</td>
</tr>
<tr>
<td>Food Technology Association of Australia</td>
<td>Industry Association</td>
<td>• Supports</td>
</tr>
<tr>
<td>Johanna Metz</td>
<td>Private</td>
<td>• Opposes</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Opposition to GM foods</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Opposes introduction of A. niger into NZ</td>
</tr>
<tr>
<td>Charlotte Huckson</td>
<td>Private</td>
<td>• Opposes</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Opposition to GM foods (campaign letter)</td>
</tr>
<tr>
<td>Karen Forno</td>
<td>Private</td>
<td>• Opposes</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Opposition to GM foods (campaign letter)</td>
</tr>
<tr>
<td>Katherine Smith</td>
<td>Private</td>
<td>• Opposes</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Opposition to GM foods (campaign letter)</td>
</tr>
<tr>
<td>Cliff Mason</td>
<td>Private</td>
<td>• Opposes</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Opposition to GM foods (campaign letter)</td>
</tr>
<tr>
<td>Jonathan Eisen</td>
<td>Private</td>
<td>• Opposes</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Opposition to GM foods (campaign letter)</td>
</tr>
<tr>
<td>Leo Adler</td>
<td>Private</td>
<td>• Opposes</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Opposition to GM foods (campaign letter)</td>
</tr>
<tr>
<td>NZFSA</td>
<td>Government</td>
<td>• Supports</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Satisfied the proposed use is technologically justified</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Satisfied there is no public health and safety concerns identified</td>
</tr>
<tr>
<td>Queensland Health (whole of Queensland Government response)</td>
<td>Government</td>
<td>• Supports</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Acknowledges:</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• the proposed use is technologically justified</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• there is no public health and safety concerns identified</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• no significant costs for government , consumers or manufacturers</td>
</tr>
<tr>
<td>Submitter</td>
<td>Group</td>
<td>Comments</td>
</tr>
<tr>
<td>------------------------</td>
<td>---------------------</td>
<td>----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
</tbody>
</table>
| Gene Ethics            | Consumer association| • Opposes  
• States the enzyme is not a ‘lipase’, is less than 82% homologous to the naturally occurring lipase in *F. culmorum*  
• Claims the enzyme has been altered by more than one third from the comparator  
• Claims no evidence has been provided to support claim of safe use and that the differences between this enzyme and natural lipase have not been fully investigated  
• Claims the enzyme has been erroneously identified, referred to and treated as ‘lipase’  
• Recommends rejection based on erroneous application of the concept of ‘substantial equivalence’  
• Cites under the ‘Precautionary Principle’, that insufficient evidence has been provided to conclude safe use in human food  
• States the novel GM enzyme is *NOT ‘lipase’*, but a novel GM enzyme being assessed under Standard 1.5.2  
  − Claims, if the enzyme were actually ‘lipase’ there would be no need to assess under Standard 1.5.2  
• Claims the bioinformatic assessment is inadequate and states multiple databases should be utilised  
• States the lipase family is among the same family as human digestive enzymes and that more evidence should be required to show how the product interacts with gluten in the digestive tract  
• Claims technological justification is weak – why need a GM enzyme when a naturally occurring lipase serves the same purpose |
| Charmaine Waldron      | Private             | • Opposes  
  − Opposition to GM foods  
    o Claims GM research is a waste of money  
    o Detrimental impact on NZ economy  
    o GM is unethical, unscientific and unacceptable |
| Franceine Waldron      | Private             | • Opposes  
  − Opposition to GM foods  
    o Claims GM research is a waste of money  
    o Detrimental impact on NZ economy  
    o GM is unethical, unscientific and unacceptable |
| Rosemary Drinnan       | Private             | • Opposes  
• Opposition to GM food  
• Requests a sample label displaying GM product |